EOS 方案与 FOLFOX4 方案治疗晚期胃癌的疗效比较简

目的：比较EOS方案与FOLFOX4方案治疗晚期胃癌的疗效和毒副反应。方法：将60例经病理证实的晚期胃癌随机分为2组，A组给予EOS方案化疗，表阿霉素50mg／m^2静注d1＋奥沙利铂135mg／m^2静滴d1＋替吉奥胶囊40mg／m^2口服d1-14，3周重复，共完成4周期；B组给予FOLFOX4方案化疗，奥沙利铂85mg／m^2静滴2小时d1＋亚叶酸钙200mg／m^2静滴2小时d1-2＋氟尿嘧啶400mg／m^2静注d1-2＋氟尿嘧啶600mg／m^2持续静滴22小时d1-2，2周重复，共完成6周期。结果：A组患者生活质量改善率为70％，近期有效率为63．3％，中位疾病进展时间为6．9个月，中位生存时间为11．6个月。B组患者分别为43．3％、36．7％、4．8个月和8．2个月。A组均显著优于B组。两组患者化疗毒副反应无差异。结论：EOS方案疗效优于FOLFOX4方案，且耐受性好，值得临床进一步研究。

Comparison of EOS regimen and FOLFOX4 regimen on advanced gastric carcinoma

Objective：To compare the efficacy and toxicity of EOS regimen and FOLFOX4 regimen on advanced gastric carcinoma. Methods：Sixty cases of advanced gastric cancer were enrolled into the study. All patients were divided into two groups. Thirty patients of group A received EOS regimen：Epirubicin 50mg/m^2 via intravenous injection on day 1,Oxaliplatin 135mg/m^2 via intravenous injection on day 1 ,S -1 40mg/m^2 via oral administration on day 1 to 14, repeated every 21 days for four cycles. Thirty patients of group B received FOLFOX4 regimen ：Oxaliplatin 85 mg/ m^2 via intravenous infusion on day 1, calcium folinate 200mg/m^2 intravenous iniusion for 2 hours on day 1 to 2,5 - FU 400mg/m^2 via intravenous injection, and 600mg/m^2 intravenous infusion for 22 hours on day 1 to 2, repeated every 14 days for six cycles. Improvement of QOL, response rate （RR） , median time to progression （TTP） , median survival time （MST） and toxicity of the two groups were analyzed. Results： In group A, improvement rate of QOL was 70% , RR was 63.3% ,TIP 6.9 months,MST 11.6 months;In group B,43.3% ,36.7% ,4.8 months,8.2 months. The difference between two groups was statistically significant（P 〈0.05 ）. The difference of the side -effects of two groups was not statistically significant（ P 〉 0.05 ）. Conclusion：EOS regimen is safe and effective on advanced gastric carcinoma. The adverse effects are tolerant.